-
Li Li Appointed as New Director of NMPA
•
The State Council has released an announcement regarding appointments and dismissals within the government. Among the changes, Li Li has been appointed to serve as the director of the National Medical Products Administration (NMPA), succeeding Jiao Hong who has left the position. Li Li’s Extensive Experience in Healthcare and AdministrationLi…
-
NHSA Mandates National Standards for Medical Consumables in Basic Medical Insurance
•
The National Healthcare Security Administration (NHSA) has released a notification with a focus on enhancing the standards for managing Basic Medical Insurance (BMI) payments for medical consumables. The notice indicates a further push towards the adoption of national BMI product codes to ensure uniformity across the country. Expanding BMI Payment…
-
Bristol-Myers Squibb Acquires Rights to Zenas BioPharma’s Obexelimab for Autoimmune Diseases
•
US pharmaceutical major Bristol-Myers Squibb (BMS; NYSE: BMY) has entered into a licensing and cooperation agreement with Zenas BioPharma, investing USD 50 million for development and commercial rights to Zenas’s obexelimab for autoimmune diseases in Japan, South Korea, Taiwan, Singapore, Hong Kong, and Australia. Under the terms of the agreement,…
-
Neurophth Biotechnology’s NFS-05 Gene Therapy Gets Australian Clinical Trial Approval for ADOA
•
China-based gene therapy specialist Neurophth Biotechnology Ltd has announced that it has received clinical trial approval from the Therapeutic Goods Administration of Australia for its candidate drug NFS-05. The therapy is set to be assessed as a treatment for autosomal dominant optic atrophy (ADOA), an inherited optic neuropathy. Understanding Autosomal…
-
MGI Tech Partners with Eight Companies to Expand G99-Based Sequencing Applications
•
China-based MGI Tech, a subsidiary of BGI Group (SHE: 300676), has entered into cooperation agreements with eight companies to develop applications based on the G99 sequencing platform. The financial details of these agreements have not been disclosed. DNBSEQ-G99: A Miniaturized Sequencing PlatformDNBSEQ-G99, launched by MGI Tech, is a miniaturized dual…
-
Harbin Gloria Pharmaceuticals’ Zimberelimab Receives NMPA Approval for Cervical Cancer Treatment
•
China-based Harbin Gloria Pharmaceuticals Co., Ltd (SHE: 002437) has announced that it has received market approval from the National Medical Products Administration (NMPA) for its programmed cell death-1 (PD-1) monoclonal antibody (mAb) zimberelimab. The drug is indicated for the treatment of recurrent or metastatic cervical cancer patients with positive PD-L1…
-
Janssen Appoints Cherry Huang as President of Xi’an Janssen in China Management Shake-Up
•
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has announced a significant management reshuffle in China. Cherry Huang, previously the North Asia Regional Managing Director and CEO of the Korea unit, will succeed Zhen Lei as the president of Xi’an Janssen. In this role, Huang will be responsible…
-
Seagen and Genmab Announce Positive Phase III Results for Tivdak in Cervical Cancer
•
Seagen (NASDAQ: SGEN), currently in the process of being acquired by Pfizer (NYSE: PFE), and its partner Genmab (NASDAQ: GMAB), have announced the achievement of the primary endpoint in a Phase III trial for their antibody-drug conjugate (ADC) Tivdak (tisotumab vedotin). The trial focuses on patients with recurrent or metastatic…
